Strategies for Zika drug discovery
Zika virus (ZIKV) can cause devastating congenital syndrome in fetuses from pregnant women and autoimmune disorder Guillain-Barré syndrome in adults. No clinically approved vaccine or drug is currently available for ZIKV. This unmet medical need has motivated a global effort to develop countermeasur...
Gespeichert in:
| Veröffentlicht in: | Current opinion in virology 2019-04, Vol.35, p.19-26 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 26 |
|---|---|
| container_issue | |
| container_start_page | 19 |
| container_title | Current opinion in virology |
| container_volume | 35 |
| creator | Zou, Jing Shi, Pei-Yong |
| description | Zika virus (ZIKV) can cause devastating congenital syndrome in fetuses from pregnant women and autoimmune disorder Guillain-Barré syndrome in adults. No clinically approved vaccine or drug is currently available for ZIKV. This unmet medical need has motivated a global effort to develop countermeasures. Several promising ZIKV vaccine candidates have already entered clinical trials. In contrast, antiviral development of ZIKV is lagging behind. Here, we review the overall strategies for ZIKV drug discovery, including (i) repurposing of clinically approved drugs, (ii) viral replication-based phenotypic screening for inhibitors, and (iii) targeted drug discovery of viral proteins. Along with vaccines, the development of antiviral treatment will provide a complementary means to control ZIKV infections. |
| doi_str_mv | 10.1016/j.coviro.2019.01.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2190120785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2190120785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-e1b523c58080d6b54540828b619760e254c52036f72dfb3bf51af608eb3ee8c63</originalsourceid><addsrcrecordid>eNo9kEFPwzAMhSMEYtPYP0Co4sSlxU6aND2iiQHSJA7AhUvUtM7UsdGRtEj792TamC_24T0_-2PsGiFDQHW_yurut_VdxgHLDDADkGdsjLooU8WVPD_NshixaQgriCUVlhIv2UiAllzkcsxu33pf9bRsKSSu88ln-1UljR-WSdOGmEF-d8UuXLUOND32CfuYP77PntPF69PL7GGR1gKKPiW0cWctNWholJW5zEFzbWNmoYC4zGvJQShX8MZZYZ3EyinQZAWRrpWYsLvD3q3vfgYKvdnEE2i9rr6pG4LhWAJyKLSM0vwgrX0Xgidntr7dVH5nEMwekFmZAyCzB2QATfw-2m6OCYPdUHMy_eMQf5XTYQo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2190120785</pqid></control><display><type>article</type><title>Strategies for Zika drug discovery</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zou, Jing ; Shi, Pei-Yong</creator><creatorcontrib>Zou, Jing ; Shi, Pei-Yong</creatorcontrib><description>Zika virus (ZIKV) can cause devastating congenital syndrome in fetuses from pregnant women and autoimmune disorder Guillain-Barré syndrome in adults. No clinically approved vaccine or drug is currently available for ZIKV. This unmet medical need has motivated a global effort to develop countermeasures. Several promising ZIKV vaccine candidates have already entered clinical trials. In contrast, antiviral development of ZIKV is lagging behind. Here, we review the overall strategies for ZIKV drug discovery, including (i) repurposing of clinically approved drugs, (ii) viral replication-based phenotypic screening for inhibitors, and (iii) targeted drug discovery of viral proteins. Along with vaccines, the development of antiviral treatment will provide a complementary means to control ZIKV infections.</description><identifier>ISSN: 1879-6257</identifier><identifier>EISSN: 1879-6265</identifier><identifier>DOI: 10.1016/j.coviro.2019.01.005</identifier><identifier>PMID: 30852345</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Animals ; Antiviral Agents - pharmacology ; Clinical Trials as Topic ; Drug Discovery - methods ; Drug Repositioning ; Humans ; Viral Vaccines - immunology ; Virus Replication - drug effects ; Zika Virus - drug effects ; Zika Virus - genetics ; Zika Virus Infection - drug therapy ; Zika Virus Infection - prevention & control</subject><ispartof>Current opinion in virology, 2019-04, Vol.35, p.19-26</ispartof><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c307t-e1b523c58080d6b54540828b619760e254c52036f72dfb3bf51af608eb3ee8c63</citedby><cites>FETCH-LOGICAL-c307t-e1b523c58080d6b54540828b619760e254c52036f72dfb3bf51af608eb3ee8c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30852345$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zou, Jing</creatorcontrib><creatorcontrib>Shi, Pei-Yong</creatorcontrib><title>Strategies for Zika drug discovery</title><title>Current opinion in virology</title><addtitle>Curr Opin Virol</addtitle><description>Zika virus (ZIKV) can cause devastating congenital syndrome in fetuses from pregnant women and autoimmune disorder Guillain-Barré syndrome in adults. No clinically approved vaccine or drug is currently available for ZIKV. This unmet medical need has motivated a global effort to develop countermeasures. Several promising ZIKV vaccine candidates have already entered clinical trials. In contrast, antiviral development of ZIKV is lagging behind. Here, we review the overall strategies for ZIKV drug discovery, including (i) repurposing of clinically approved drugs, (ii) viral replication-based phenotypic screening for inhibitors, and (iii) targeted drug discovery of viral proteins. Along with vaccines, the development of antiviral treatment will provide a complementary means to control ZIKV infections.</description><subject>Animals</subject><subject>Antiviral Agents - pharmacology</subject><subject>Clinical Trials as Topic</subject><subject>Drug Discovery - methods</subject><subject>Drug Repositioning</subject><subject>Humans</subject><subject>Viral Vaccines - immunology</subject><subject>Virus Replication - drug effects</subject><subject>Zika Virus - drug effects</subject><subject>Zika Virus - genetics</subject><subject>Zika Virus Infection - drug therapy</subject><subject>Zika Virus Infection - prevention & control</subject><issn>1879-6257</issn><issn>1879-6265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEFPwzAMhSMEYtPYP0Co4sSlxU6aND2iiQHSJA7AhUvUtM7UsdGRtEj792TamC_24T0_-2PsGiFDQHW_yurut_VdxgHLDDADkGdsjLooU8WVPD_NshixaQgriCUVlhIv2UiAllzkcsxu33pf9bRsKSSu88ln-1UljR-WSdOGmEF-d8UuXLUOND32CfuYP77PntPF69PL7GGR1gKKPiW0cWctNWholJW5zEFzbWNmoYC4zGvJQShX8MZZYZ3EyinQZAWRrpWYsLvD3q3vfgYKvdnEE2i9rr6pG4LhWAJyKLSM0vwgrX0Xgidntr7dVH5nEMwekFmZAyCzB2QATfw-2m6OCYPdUHMy_eMQf5XTYQo</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Zou, Jing</creator><creator>Shi, Pei-Yong</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201904</creationdate><title>Strategies for Zika drug discovery</title><author>Zou, Jing ; Shi, Pei-Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-e1b523c58080d6b54540828b619760e254c52036f72dfb3bf51af608eb3ee8c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antiviral Agents - pharmacology</topic><topic>Clinical Trials as Topic</topic><topic>Drug Discovery - methods</topic><topic>Drug Repositioning</topic><topic>Humans</topic><topic>Viral Vaccines - immunology</topic><topic>Virus Replication - drug effects</topic><topic>Zika Virus - drug effects</topic><topic>Zika Virus - genetics</topic><topic>Zika Virus Infection - drug therapy</topic><topic>Zika Virus Infection - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zou, Jing</creatorcontrib><creatorcontrib>Shi, Pei-Yong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zou, Jing</au><au>Shi, Pei-Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Strategies for Zika drug discovery</atitle><jtitle>Current opinion in virology</jtitle><addtitle>Curr Opin Virol</addtitle><date>2019-04</date><risdate>2019</risdate><volume>35</volume><spage>19</spage><epage>26</epage><pages>19-26</pages><issn>1879-6257</issn><eissn>1879-6265</eissn><abstract>Zika virus (ZIKV) can cause devastating congenital syndrome in fetuses from pregnant women and autoimmune disorder Guillain-Barré syndrome in adults. No clinically approved vaccine or drug is currently available for ZIKV. This unmet medical need has motivated a global effort to develop countermeasures. Several promising ZIKV vaccine candidates have already entered clinical trials. In contrast, antiviral development of ZIKV is lagging behind. Here, we review the overall strategies for ZIKV drug discovery, including (i) repurposing of clinically approved drugs, (ii) viral replication-based phenotypic screening for inhibitors, and (iii) targeted drug discovery of viral proteins. Along with vaccines, the development of antiviral treatment will provide a complementary means to control ZIKV infections.</abstract><cop>Netherlands</cop><pmid>30852345</pmid><doi>10.1016/j.coviro.2019.01.005</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1879-6257 |
| ispartof | Current opinion in virology, 2019-04, Vol.35, p.19-26 |
| issn | 1879-6257 1879-6265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2190120785 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Antiviral Agents - pharmacology Clinical Trials as Topic Drug Discovery - methods Drug Repositioning Humans Viral Vaccines - immunology Virus Replication - drug effects Zika Virus - drug effects Zika Virus - genetics Zika Virus Infection - drug therapy Zika Virus Infection - prevention & control |
| title | Strategies for Zika drug discovery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T05%3A22%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Strategies%20for%20Zika%20drug%20discovery&rft.jtitle=Current%20opinion%20in%20virology&rft.au=Zou,%20Jing&rft.date=2019-04&rft.volume=35&rft.spage=19&rft.epage=26&rft.pages=19-26&rft.issn=1879-6257&rft.eissn=1879-6265&rft_id=info:doi/10.1016/j.coviro.2019.01.005&rft_dat=%3Cproquest_cross%3E2190120785%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2190120785&rft_id=info:pmid/30852345&rfr_iscdi=true |